Paroxysmal Nocturnal Hemoglobinuria Therapeutics Market To Register a Hugh Growth In Healthcare Industry by 2026 With Top Players Alexion Pharmaceuticals, Akari therapeutics, Apellis Pharmaceuticals, Amgen Inc, CinnaGen Co
Symptoms of paroxysmal nocturnal hemoglobinuria includes hemolytic anemia, hemoglobinuria, fatigue, breathlessness, abdominal pain, difficulty in controlling bleeding even from very minor wounds, appearance of small red dots on the skin that indicates bleeding under the skin, severe headache, and blood clots (thrombosis). Bone marrow transplant (stem cell transplant) is the only curative therapy for paroxysmal nocturnal hemoglobinuria available so far.
Request Sample Copy of This Business Report @ https://www.coherentmarketinsights.com/insight/request-sample/2542
Global Paroxysmal Nocturnal Hemoglobinuria Therapeutics Market: Drivers
The global paroxysmal nocturnal hemoglobinuria therapeutics market size is expected to witness significant growth over the forecast period, owing to increasing demand for PNH therapeutics and rising number of treatment approvals from the U.S. Food and Drug Administration (FDA) for PNH, which includes iron supplements, blood transfusion, blood thinner, Eculizumab (Soliris), and bone marrow transplant. According to a study published in Blood Journal in 2012, the 5 year survival-rate of patients treated with Soliris is 95.5%.
Moreover, new R&D studies are being conducted for development of cost-effective PNH treatment, which is expected to drive the paroxysmal nocturnal hemoglobinuria therapeutics market revenue. For instance, in 2014, the research team of Perelman School of Medicine at Pennsylvania, U.S. investigated a compound named PEG-Cp40, which is long-acting and cost-effective for the treatment of paroxysmal nocturnal hemoglobinuria.
Global Paroxysmal Nocturnal Hemoglobinuria Therapeutics Market: Restraints
The paroxysmal nocturnal hemoglobinuria therapeutics market revenue is expected to hamper because of high cost for the treatment of paroxysmal nocturnal hemoglobinuria. For instance, in 2017, the American Council on Science and Health (ACSH) declared Eculizumab (Soliris) as the most expensive drug in the U.S. and cost of Solirirs ranges up to US$ 500,000 per person per year.
Moreover, the side effects shown by the drug Soliris such as headache, fatigue, nausea, vomiting, diarrhea, muscle pain, and nasal congestion can also negatively impact the paroxysmal nocturnal hemoglobinuria therapeutics market size. There are some serious side effects also, which includes low White Blood Cell (WBC) count, increased chances of bacterial infections such as meningitis, and bacterial sinusitis. According to the Centers for Disease Control and Prevention (CDC) reports of 2017, patients under the therapy of Eculizumab (Soliris) are at 1,000 to 2,000 times greater at risk of getting meningococcal diseases han the healthy individuals in the U.S.
Global Paroxysmal Nocturnal Hemoglobinuria Therapeutics Market: Competitive Landscape
Key players operating in the global paroxysmal nocturnal hemoglobinuria therapeutics market include Alexion Pharmaceuticals, Akari therapeutics, Apellis Pharmaceuticals, Amgen Inc, CinnaGen Co, Ra Pharmaceuticals Inc, Alnylam Pharmaceuticals, Achillion Pharmaceuticals Inc, Novartis, Roche, and Regeneron Pharmaceuticals.
Put Your Queries To Our Analyst @ https://www.coherentmarketinsights.com/insight/talk-to-analyst/2542
Global Paroxysmal Nocturnal Hemoglobinuria Therapeutics Market: Regional Analysis
North America is expected to dominate in paroxysmal nocturnal hemoglobinuria therapeutics market during the forecast period, owing to new approvals from the FDA. For instance, in 2018, Ravulizumab (Ultomiris) from Alexion Pharmaceuticals and APL2 from Apellis Pharmaceuticals was approved by the FDA, for the treatment of paroxysmal nocturnal hemoglobinuria.
Asia Pacific paroxysmal nocturnal hemoglobinuria therapeutics market size is expected to witness significant growth due to availability of cost-effective treatment and medical tourism for PNH. According to an article published by National Center for Biotechnology Information (NCBI) in 2014, the cost of bone marrow transplant in India was between US$ 10,000 and US$ 40,000 in 2014 and in the U.S., it was between US$ 73,000 and US$ 140,000 in 2012.
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Coherent Market Insights
1001 4th Ave,
Seattle, WA 98154
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Paroxysmal Nocturnal Hemoglobinuria Therapeutics Market To Register a Hugh Growth In Healthcare Industry by 2026 With Top Players Alexion Pharmaceuticals, Akari therapeutics, Apellis Pharmaceuticals, Amgen Inc, CinnaGen Co here
News-ID: 1655146 • Views: 535
More Releases from Coherent Market Insights - Pharmaceutical Industry
Radiopharmaceuticals in Nuclear Medicine Market Advancements to Watch Out For 20 …
Coherent Market Insights released a new market study on 2018-2026 Radiopharmaceuticals Market with 100+ market data Tables, Pie Chat, Graphs & Figures spread through Pages and easy to understand detailed analysis. At present, the market is developing its presence. The Research report presents a complete assessment of the Market and contains a future trend, current growth factors, attentive opinions, facts, and industry validated market data. Ask For Sample Copy of Research
Outsourced Drug Discovery Market: Latest Advancements & Market Outlook 2019 to 2 …
Outsourced drug discovery is a contract-based process, which is conducted by the contract research organizations (CRO) and contract manufacturing organization (CMO). Contract research organization provides support to pharmaceutical, biotechnology, and medical device industries for drug discovery and development. CRO facilitates the various services such as biopharmaceutical development, biologic assay development, preclinical research, clinical trials, and pharmacovigilance, for drug discovery and development. Ask For a Sample Copy of This Business Report @
Cannabis Testing Services Market: New Business Opportunities and Investment Rese …
Cannabis market is highly influenced by rigorous legalization efforts, which are aiming for approval of cannabis for medicinal or recreational purpose. Various governments and regulatory authorities are taking efforts to legalize cannabis, owing to its medicinal benefits. Moreover, commercialization of cannabis-based products under the legalized standards require successful cannabis testing, which further results in lucrative growth opportunity for market players. Ask For a Sample Copy of This Business Report @ https://www.coherentmarketinsights.com/insight/request-sample/2976 Market
Global Myelodysplastic Syndrome (MDS) Treatment Market Balenced To Reach Insigni …
Myelodysplastic syndrome (MDS) is a disorder, which affects the bone marrow and produces immature blood cells. Bone marrow failure leads to lowering the levels of healthy blood cells circulation in the bloodstream. According to Seattle Cancer Care Alliance, around 80%-85% of people with MDS have more cells in their bone marrow than healthy people. According to National Organization for Rare Disorders, MDS deteriorates into a form of cancer in around
More Releases for Paroxysmal
Paroxysmal Nocturnal Hemoglobinuria Market Report 2020-2030
Forecasts by Treatment (Medication, Stem Cell Transplant, Blood Transfusion) Plus Analysis of Leading Companies Download free sample pages: https://www.visiongain.com/report/paroxysmal-nocturnal-hemoglobinuria-market-report-2020-2030/ Paroxysmal Nocturnal Hemoglobinuria Market- our new study reveals trends, R&D progress, and predicted revenues Where the Paroxysmal Nocturnal Hemoglobinuria is market heading? If you are involved in this industry you must read this newly updated report. Visiongain's report shows you the potential revenues streams to 2030, assessing data, trends, opportunities and business prospects
Paroxysmal Nocturnal Hemoglobinuria - Pipeline by Companies , H2 2017
WiseGuyReports.com with their unique quality of simplifying the market research study, presents a deep diving study report “Paroxysmal Nocturnal Hemoglobinuria - Pipeline Review, H2 2017” Paroxysmal Nocturnal Hemoglobinuria Overview Paroxysmal nocturnal hemoglobinuria is a rare disease in which red blood cells break down earlier than normal. Symptoms include abdominal pain, back pain, dark urine, easy bruising or bleeding, headache and shortness of breath. The predisposing factors include age, obesity and hormone therapy. Treatment
Paroxysmal Nocturnal Hemoglobinuria - Pipeline Review, H2 2017
"The Report Paroxysmal Nocturnal Hemoglobinuria - Pipeline Review, H2 2017 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz" Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Paroxysmal Nocturnal Hemoglobinuria - Pipeline Review, H2 2017, provides an overview of the Paroxysmal Nocturnal Hemoglobinuria (Hematological Disorders) pipeline landscape. Paroxysmal nocturnal hemoglobinuria is a rare disease in which red blood cells break down earlier
Paroxysmal Nocturnal Hemoglobinuria Pipeline Insight and Therapeutic Assessment …
Market Research Hub (MRH) has recently broadcasted a new study to its broad research portfolio, which is titled as “Paroxysmal Nocturnal Hemoglobinuria-Pipeline Insights, 2017, report provides comprehensive insights of the ongoing therapeutic research and development across Paroxysmal Nocturnal Hemoglobinuria. The report provides a complete understanding of the pipeline activities covering all clinical, pre-clinical and discovery stage products. A comparative pipeline therapeutics assessment of Paroxysmal Nocturnal Hemoglobinuria by development stage, therapy type,
Paroxysmal Nocturnal Hemoglobinuria Therapeutic Pipeline Analysis, 2017 Clinical …
Paroxysmal Nocturnal Hemoglobinuria (PNH) is a rare life-threatening disease characterized by destruction of red blood cells, blood clots, and compromised bone marrow function. Some of the symptoms of the disease include abdominal and back pain, dark urine, easy bruising or bleeding, fatigue or weakness, headache and shortness of breath. The risk factors for PNH include age, obesity and hormone therapy. According to the Johns Hopkins Medicine, approximately, one to one
Paroxysmal Nocturnal Hemoglobinuria - Pipeline Review, H1 2017
ReportsWorldwide has announced the addition of a new report title Paroxysmal Nocturnal Hemoglobinuria - Pipeline Review, H1 2017 to its growing collection of premium market research reports. Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Paroxysmal Nocturnal Hemoglobinuria - Pipeline Review, H1 2017, provides an overview of the Paroxysmal Nocturnal Hemoglobinuria (Hematological Disorders) pipeline landscape. Paroxysmal nocturnal hemoglobinuria is a rare disease in which red blood cells break down earlier